Linked Data API

Show Search Form

Search Results

1665019
registered interest false more like this
date less than 2023-10-16more like thismore than 2023-10-16
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Lung Diseases: Health Education more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase awareness of pulmonary fibrosis. more like this
tabling member constituency York Outer remove filter
tabling member printed
Julian Sturdy more like this
uin 202713 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-10-19more like thismore than 2023-10-19
answer text <p>Patients with pulmonary fibrosis are cared for by National Health Service regional specialist Interstitial Lung Disease (ILD) services, who are commissioned by NHS England. To be referred to a specialist service patients need to be identified in primary and secondary care. Early and accurate diagnosis is a priority for NHS England, and the work to improve this area of clinical care is underway, which should have an impact on reducing delayed diagnosis of pulmonary fibrosis.</p><p>NHS England is responsible for the commissioning of services for ILD and funds the cost of anti-fibrotic treatments to treat this disease. Access to these treatments has recently been expanded to patients with non-idiopathic pulmonary fibrosis following the publication of the National Institute for Health and Care Excellence’s technology appraisal ‘Nintedanib for treating progressive fibrosing interstitial lung diseases’ in November 2021.</p><p>The Department has no plans for an awareness campaign.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
grouped question UIN 202714 more like this
question first answered
less than 2023-10-19T15:57:32.3Zmore like thismore than 2023-10-19T15:57:32.3Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4079
label Biography information for Julian Sturdy more like this
1665020
registered interest false more like this
date less than 2023-10-16more like thismore than 2023-10-16
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Lung Diseases: Diagnosis and Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access to (a) early diagnosis and (b) treatment for people living with pulmonary fibrosis. more like this
tabling member constituency York Outer remove filter
tabling member printed
Julian Sturdy more like this
uin 202714 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-10-19more like thismore than 2023-10-19
answer text <p>Patients with pulmonary fibrosis are cared for by National Health Service regional specialist Interstitial Lung Disease (ILD) services, who are commissioned by NHS England. To be referred to a specialist service patients need to be identified in primary and secondary care. Early and accurate diagnosis is a priority for NHS England, and the work to improve this area of clinical care is underway, which should have an impact on reducing delayed diagnosis of pulmonary fibrosis.</p><p>NHS England is responsible for the commissioning of services for ILD and funds the cost of anti-fibrotic treatments to treat this disease. Access to these treatments has recently been expanded to patients with non-idiopathic pulmonary fibrosis following the publication of the National Institute for Health and Care Excellence’s technology appraisal ‘Nintedanib for treating progressive fibrosing interstitial lung diseases’ in November 2021.</p><p>The Department has no plans for an awareness campaign.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
grouped question UIN 202713 more like this
question first answered
less than 2023-10-19T15:57:32.273Zmore like thismore than 2023-10-19T15:57:32.273Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4079
label Biography information for Julian Sturdy more like this
1663068
registered interest false more like this
date less than 2023-10-13more like thismore than 2023-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Dementia: Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure that new disease-modifying treatments for dementia will be available on the NHS. more like this
tabling member constituency York Outer remove filter
tabling member printed
Julian Sturdy more like this
uin 200922 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-10-19more like thismore than 2023-10-19
answer text <p>To be made routinely available to National Health Service patients in England, new medicines must receive a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) and a positive recommendation from the National Institute for Health and Care Excellence (NICE) to demonstrate clinical and cost effectiveness.</p><p>A number of potential new disease modifying treatments for Alzheimer’s disease are in development and MHRA, NICE, NHS England and the Department are working closely to ensure that arrangements are in place to support the adoption of any new licensed and NICE recommended treatment for Alzheimer’s disease as soon as possible.</p><p>NICE’s appraisal of lecanemab for treating early Alzheimer's disease is currently underway and, subject to licensing and the company engaging in the process, NICE expects to publish final guidance in July 2024 as close to licence as possible. NICE is also due to begin its appraisal of donanemab for treating early Alzheimer’s disease later this year.</p><p>To prepare for these appraisals, and the expected pipeline of further disease modifying dementia treatments, the NICE Health Technology Assessment Innovation Laboratory has already started working on identifying potential challenges that might face the evaluation of these medicines and ways of addressing them.</p>
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-10-19T14:38:04.853Zmore like thismore than 2023-10-19T14:38:04.853Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4079
label Biography information for Julian Sturdy more like this
1663630
registered interest false more like this
date less than 2023-10-13more like thismore than 2023-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Epilepsy: Health Services more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help support people living with epilepsy. more like this
tabling member constituency York Outer remove filter
tabling member printed
Julian Sturdy more like this
uin 201484 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-10-19more like thismore than 2023-10-19
answer text <p>The majority of health services for people with epilepsy are commissioned locally by integrated care boards (ICBs). ICBs are best placed to make decisions regarding the provision of health services to their local population, including for the treatment of epilepsy, subject to local prioritisation and funding.</p><p>At a national level, there are several initiatives supporting service improvement for those with epilepsy, including NHS England’s Neuroscience Service Transformation Programme and RightCare Epilepsy Toolkit.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-10-19T16:16:01.423Zmore like thismore than 2023-10-19T16:16:01.423Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4079
label Biography information for Julian Sturdy more like this
1663631
registered interest false more like this
date less than 2023-10-13more like thismore than 2023-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs: Patients more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help manage the (a) affordability and (b) value for money in the cost of medicines purchased by patients. more like this
tabling member constituency York Outer remove filter
tabling member printed
Julian Sturdy more like this
uin 201485 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-10-19more like thismore than 2023-10-19
answer text <p>The Department has no role in the costs of medicines purchased in the private sector.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-10-19T14:42:20.233Zmore like thismore than 2023-10-19T14:42:20.233Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4079
label Biography information for Julian Sturdy more like this
1663632
registered interest false more like this
date less than 2023-10-13more like thismore than 2023-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Palliative Care more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help support patients receiving end-of-life care. more like this
tabling member constituency York Outer remove filter
tabling member printed
Julian Sturdy more like this
uin 201486 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-10-19more like thismore than 2023-10-19
answer text <p>As set out in the Health and Care Act 2022, it is the legal duty of integrated care boards (ICBs) to commission palliative and end of life care to meet the needs of their local population. To support commissioners to fulfil this duty, NHS England has published statutory guidance and service specifications for both adults, and children and young people, which provide guidance to ICBs on enabling high-quality commissioning of services that meet both population need and preferences.</p><p>In addition, ICBs are supported by Palliative and End of Life Care Strategic Clinical Networks which work to progress and implement sustainable commissioning models for equitable, high-quality services.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-10-19T16:17:22.107Zmore like thismore than 2023-10-19T16:17:22.107Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4079
label Biography information for Julian Sturdy more like this
1663633
registered interest false more like this
date less than 2023-10-13more like thismore than 2023-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether the Government is taking steps to reduce inequalities in access to medicinal cannabis prescribed under the NHS. more like this
tabling member constituency York Outer remove filter
tabling member printed
Julian Sturdy more like this
uin 201487 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-10-19more like thismore than 2023-10-19
answer text <p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p>Funding of unlicensed products is subject to local National Health Service decisions on a case-by-case basis. These decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality, and clinical and cost effectiveness.</p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-10-19T14:43:27.227Zmore like thismore than 2023-10-19T14:43:27.227Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4079
label Biography information for Julian Sturdy more like this
1658209
registered interest false more like this
date less than 2023-09-05more like thismore than 2023-09-05
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Leukaemia: Health Services more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps the Government is taking to support people who have been diagnosed with leukaemia. more like this
tabling member constituency York Outer remove filter
tabling member printed
Julian Sturdy more like this
uin 197734 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-09-11more like thismore than 2023-09-11
answer text <p>The Department has taken steps to ensure that the National Health Service prioritises cancer treatment, including leukaemia. The NHS Long Term Plan states that, where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan and health and wellbeing information and support. This includes provision of end of treatment summaries, empowering people to manage their care and the impact of their cancer. To support delivery of our cancer care priorities, including expanding treatment capacity across NHS hospital trusts, NHS England is providing over £390 million in cancer service development funding to Cancer Alliances.</p><p>More treatment is happening, with over 335,000 people receiving their first cancer treatment in the 12 months leading up to June 2023, representing an increase of more than 22,000 on the same period pre-pandemic. More information on cancer waiting times is available at the following link:</p><p><a href="https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/" target="_blank">https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/</a></p><p>We are committed to ensuring that all cancer patients get access to interventions, ensuring care is focused on what matters most to each person.</p>
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-09-11T16:43:15.743Zmore like thismore than 2023-09-11T16:43:15.743Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4079
label Biography information for Julian Sturdy more like this
1658213
registered interest false more like this
date less than 2023-09-05more like thismore than 2023-09-05
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Attention Deficit Hyperactivity Disorder: Diagnosis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to increase the efficiency of accessing ADHD diagnosis. more like this
tabling member constituency York Outer remove filter
tabling member printed
Julian Sturdy more like this
uin 197737 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-09-11more like thismore than 2023-09-11
answer text <p>I refer the hon. Member to the answer I gave to the Rt hon. Member for Leeds Central on 5 April 2023 to Question <a href="https://questions-statements.parliament.uk/written-questions/detail/2023-03-28/175511" target="_blank">175511</a>.</p> more like this
answering member constituency Lewes more like this
answering member printed Maria Caulfield more like this
question first answered
less than 2023-09-11T13:40:02.827Zmore like thismore than 2023-09-11T13:40:02.827Z
answering member
4492
label Biography information for Maria Caulfield more like this
tabling member
4079
label Biography information for Julian Sturdy more like this
1658214
registered interest false more like this
date less than 2023-09-05more like thismore than 2023-09-05
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Autism: Health Services more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent steps his Department has taken to help support people living with autism. more like this
tabling member constituency York Outer remove filter
tabling member printed
Julian Sturdy more like this
uin 197738 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-09-12more like thismore than 2023-09-12
answer text <p>We expect integrated care boards (ICBs) to have due regard to relevant National Institute for Health and Care Excellence (NICE) guidelines on autism when commissioning services. It is the responsibility of ICBs to make available appropriate provision to meet the health and care needs of their local population, in line with these NICE guidelines.</p><p>Additionally, each ICB must have an Executive Lead for learning disability and autism to support them to deliver care and support for autistic people in their area. NHS England has published statutory guidance on these Executive Lead roles.</p><p> </p><p>On 5 April 2023, NHS England published a national framework and operational guidance for autism assessment services. These documents include guidance on the provision of post-diagnostic support delivered shortly after diagnosis. In 2023/24, £4.2 million is available to improve services for autistic children and young people, as well as pre and post diagnostic support, including the continuation of the ‘Autism in Schools’ programme.</p><p> </p><p>This year, the Department is also working on updating the Statutory Guidance on Autism to support the National Health Service and local authorities to deliver improved outcomes for autistic people.</p><p>From 1 July 2022, the Health and Care Act 2022 requires Care Quality Commission registered providers to ensure their staff receive specific training on learning disability and autism appropriate to their role. We are rolling out the Oliver McGowan Mandatory Training on Learning Disability and Autism to support this. This training will help to ensure that staff have the right skills and knowledge to provide safe and compassionate care, including how to provide reasonable adjustments, for autistic people.</p>
answering member constituency Lewes more like this
answering member printed Maria Caulfield more like this
question first answered
less than 2023-09-12T11:16:13.35Zmore like thismore than 2023-09-12T11:16:13.35Z
answering member
4492
label Biography information for Maria Caulfield more like this
tabling member
4079
label Biography information for Julian Sturdy more like this